US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist

685.660
+5.660+0.83%

Close Feb 19 16:00 ET

685.660
0.0000.00%

Post 20:01 ET

74.96BMarket Cap17.88P/E (TTM)

Regeneron Pharmaceuticals Stock Forum

TRIUMPHANT RETURNS

Yesterday 06:38

LOTS OF NOTABLE NAMES IN THIS STOCK!

$Novo-Nordisk A/S (NVO.US)$ $Moderna (MRNA.US)$ $Johnson & Johnson (JNJ.US)$ $Netflix (NFLX.US)$ $Uber Technologies (UBER.US)$ $Grab Holdings (GRAB.US)$ $ParkwayLife Reit (C2PU.SG)$ $Tempus AI (TEM.US)$ $Serve Robotics (SERV.US)$ $Tesla (TSLA.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $Amgen (AMGN.US)$

Share Your Profit/Loss

韭菜变主力

Feb 4 10:54

$Regeneron Pharmaceuticals (REGN.US)$ In traditional technical analysis, you would think this is likely reversed given the engulfing pattern with strong volume at an earnings event. But in this trending market, a higher high has to be established.

10xStockPicks

Jan 23 07:47

Today 3 Analysts Place BUY Ratings On This $2 Stock $7,$9 & $16 Which Is An Acquisition Target by BIG Pharma

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...

韭菜变主力

Jan 13 16:45

$Regeneron Pharmaceuticals (REGN.US)$ Wow, that was a nice dip buying. I didn’t follow their events closely. I bought back somewhat early on Jan 10.

韭菜变主力

Jan 10 13:12

$Regeneron Pharmaceuticals (REGN.US)$ It’s doing this kind of thing. Kind of scary. Nobody wants it for above 700.

韭菜变主力

Jan 7 23:51

$Regeneron Pharmaceuticals (REGN.US)$ This is in NDX and could benefit from the weakness of mega-cap tech stocks in the index.

韭菜变主力

Dec 31 16:47

$Regeneron Pharmaceuticals (REGN.US)$Nice. It’s quiet here and just broke the steep down trend.

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...